Literature DB >> 12557271

In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers.

Teresa A Podruchny1, Catherine Connolly, Arun Bokde, Peter Herscovitch, William C Eckelman, Dale O Kiesewetter, Trey Sunderland, Richard E Carson, Robert M Cohen.   

Abstract

The precise effects of normal aging on the cholinergic system are unknown, as both in vitro and PET studies have shown conflicting results. In vivo determination of muscarinic receptor distribution and density has been hampered by both poor subtype selectivity and/or blood-brain barrier permeability of known ligands. Previous in vitro and in vivo work with the F-18 labeled muscarinic agonist, 3-(3- (3-[(18)F]Flouropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine ((18)FP-TZTP) suggested the use of (18)FP-TZTP to selectively quantify M2 receptors in humans. In this study, we used (18)FP-TZTP to infer M2 receptor avidity in the brains of 15 healthy younger subjects (mean age = 28.3 +/- 5.5 years) and 20 healthy older subjects (mean age = 62.1 +/- 7.7 years). Corrections for subject motion during the 120-min acquisition and partial voluming (PVC) were performed. A one-tissue compartment model was used to estimate the volumes of distribution (V(T)) of (18)FP-TZTP. Within both groups of subjects, volumes of distribution (K(1)/k(2)) in cortical, subcortical, and cerebellar areas were consistent with M2 receptor topography. Compared to younger subjects older subjects had significantly higher means and standard deviations for the volumes of distribution of (18)FP-TZTP throughout much of the cerebellum, cortex, and subcortex (Global Gray V(T) = 742 +/- 163 in older subjects and 645 +/- 74 in younger subjects, P < 0.03). Across all subjects (18)FP-TZTP, regional, and Global Gray distribution volumes were significantly correlated to age (Global Gray V(T,) r = 0.41, P < 0.01). A lower concentration of acetylcholine in the synapse of some older subjects is one possible explanation for the data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557271     DOI: 10.1002/syn.10165

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

1.  Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor?

Authors:  L Ravasi; D O Kiesewetter; K Shimoji; G Lucignani; W C Eckelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

2.  Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.

Authors:  Kathryn A Chung; Brenna M Lobb; John G Nutt; Fay B Horak
Journal:  Neurology       Date:  2010-09-01       Impact factor: 9.910

3.  Clinical translation of neuroimaging research in mood disorders.

Authors:  Jakub Z Konarski; Roger S McIntyre; Joanna K Soczynska; Alexandra Bottas; Sidney H Kennedy
Journal:  Psychiatry (Edgmont)       Date:  2006-02

4.  Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys.

Authors:  Shigeyuki Yamamoto; Shingo Nishiyama; Masahiro Kawamata; Hiroyuki Ohba; Tomoyasu Wakuda; Nori Takei; Hideo Tsukada; Edward F Domino
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

5.  Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET.

Authors:  Alicia E Reid; Yu-Shin Ding; William C Eckelman; Jean Logan; David Alexoff; Colleen Shea; Youwen Xu; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

Review 6.  Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.

Authors:  Kjell Någren; Christer Halldin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-22       Impact factor: 9.236

Review 7.  Update on PET Tracer Development for Muscarinic Acetylcholine Receptors.

Authors:  Marius Ozenil; Jonas Aronow; Marlon Millard; Thierry Langer; Wolfgang Wadsak; Marcus Hacker; Verena Pichler
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-02

8.  Synthesis and in vitro evaluation of novel nortropane derivatives as potential radiotracers for muscarinic m(2) receptors.

Authors:  Remco J J Knol; Jan C van den Bos; Anton G M Janssen; Kora de Bruin; Berthe L F van Eck-Smit; Jan Booij
Journal:  Int J Mol Imaging       Date:  2011-06-13

Review 9.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

Review 10.  Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.

Authors:  Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga
Journal:  Med Res Rev       Date:  2018-11-18       Impact factor: 12.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.